Clip
Synthetic biology platform companies go public with multi-billion-dollar valuations
1:08:14 - 1:11:31 (03:17)
Ginkgo Bioworks and Zymergen, two synthetic biology platform companies, are going public via SPACs at multi-billion-dollar market caps with low revenues, signaling a significant moment for the field of synthetic biology.